SphingoTec is pleased to announce the following appointments to its management team: Deborah Bergmann as Managing Director and Chief Executive Officer (CEO), Dr. Florian Uhle as Managing Director and…
Independent of common comorbidities (e.g. hypertension and diabetes) and the frequently occurring inflammation in critically ill patients, rising penKid blood levels [1] predict acute kidney injury…
A new, improved formula has been developed for estimating the GFR using kidney function biomarker penKid. According to the data, penKid strongly correlates with the measured GFR (mGFR), while the…
A new study and real-world data on the kidney function biomarker penKid underline its potential to monitor kidney function during acute kidney injury (AKI) and RRT and to support liberation decisions…
The MDA solidifies the partnership between Boditech and SphingoTec, aiming to support the successful commercialization of the assay for the biomarker penKid on the AFIAS platforms.
The global burden of sepsis world-wide counts for 49 million cases a year, with a high mortality rate of 11 million deaths. Recent research has identified new molecules that are informative and help…
SphingoTec develops and markets innovative in vitro diagnostic (IVD) tests for novel and proprietary biomarkers for the diagnosis, prediction and monitoring of acute medical conditions, such as…
Welcome to our blog!
Here’s where we will share current and exciting information about acute care diagnostics, innovative biomarkers, recent research and development stories. We will also have guest…
The Acute Disease Quality Initiative (ADQI) has published a consensus statement that strongly recommends using innovative biomarkers to improve the management of sepsis-associated acute kidney injury…
